市場調查報告書
商品編碼
1464769
慢性發炎去髓鞘化多發性神經病變市場:按治療、診斷和最終用戶分類 - 全球預測 2024-2030Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment (Corticosteroids, Intravenous Immunoglobulin (IVIG), Physiotherapy), Diagnosis (Blood & Urine Tests, Electrodiagnostic Testing, Lumbar Puncture), End-Use - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年慢性發炎去髓鞘化神經病變市場規模為23.5億美元,2024年達24.9億美元,2030年達34.9億美元,複合年成長率為5.81%。
慢性發炎去髓鞘化多發性神經病變 (CIDP) 是一種神經肌肉或自體免疫疾病,分類為腿部和手臂感覺功能受損。此疾病是由於免疫系統錯誤地攻擊神經的保護膜(也稱為髓鞘)引起的。結果,神經訊號傳導減慢,導致肌肉無力、反射減弱和感覺障礙。 CIDP是一種慢性疾病,也是神經病學中最重要的疾病之一,因為它對患者的生活品質有重大影響。快速識別和適當的治療性介入對於控制症狀和改善結果至關重要,這凸顯了持續研究和開發針對這種衰弱性疾病的治療方法的重要性。對神經系統疾病的日益關注以及政府支持這些疾病治療的積極努力正在推動對 CIDP 治療的需求。然而,與 CIDP 相關的高成本對製造商和最終用戶來說是一個重大挑戰。公司不斷致力於研發 (R&D),推出新藥以在這個時代保持敏捷。此外,CIDP 診斷和治療方面的技術創新正在改善患者的治療效果並推動需求。創新研發包括開發更有效、侵入性更小的治療方法、開發用於早期準確檢測的新型診斷工具以及探索CIDP的遺傳基礎以發現新的治療標靶等。
主要市場統計 | |
---|---|
基準年[2023] | 23.5億美元 |
預測年份 [2024] | 24.9億美元 |
預測年份 [2030] | 34.9億美元 |
複合年成長率(%) | 5.81% |
透過增加靜脈注射人類免疫球蛋白 G 治療 CIDP 的使用來改善患者預後
慢性發炎去髓鞘化多發性神經病變 (CIDP) 的治療包括一種整體方法,旨在抑制不適當的免疫反應,同時改善患者的生活品質。治療通訊協定的第一線是靜脈注射靜脈注射(IVIG),它提供調節免疫系統功能的抗體。潑尼松等皮質類固醇可以減輕發炎並調節免疫系統活力,同樣重要。血漿去除術是一種替代策略,涉及血液淨化,以去除對這些治療沒有反應的患者的有害抗體。物理治療在CIDP的綜合治療中起著至關重要的作用,其目的是維持和提高肌肉力量、靈活性和可操作性。
最終使用者:擴大 CIDP 在醫院和診所治療的可能性,使有效的治療方法更廣泛地獲得。
醫院已成為初步診斷和治療的重要設施,提供包括靜脈注射免疫球蛋白(IVIg)治療在內的全面護理,這需要專門的醫療設備和專業知識。專科診所由具有 CIDP 深入知識的專業人員提供持續管理和專業治療,提供強化治療方法。居家照護越來越受到人們的關注,以保持護理的連續性,特別是在包括皮下免疫球蛋白 (SCIg) 治療在內的長期治療中。這些設定中的每一種都提供不同的益處並滿足 CIDP 患者群體的特定需求,確保廣泛獲得有效的治療方法。
區域洞察
在美洲,特別是在美國和加拿大,對 CIDP 的認知和診斷不斷增加,對有效治療的需求也在增加。以患者為中心的醫療保健系統和高購買力推動了客戶對創新治療方法的強烈購買行為。龐大的研發投資和有利的醫療政策正在支持 CIDP 市場的成長。 FDA 最近核准了 CIDP 治療,證實了該地區對解決這種使人衰弱的疾病的承諾。另一方面,歐盟 (EU) 國家在 CIDP 認知、診斷和治療取得方面存在不同的情況。歐盟的醫療體系優先考慮公平獲取,包括 CIDP 在內的不同國家採取了不同的模式來支持罕見疾病治療。最近的歐盟範圍內的舉措著重於加強研究、簡化監管途徑和促進跨境醫療合作,旨在改善整個歐洲大陸的病患治療效果。由於醫療保健支出的增加和診斷能力的提高,中國、日本和印度等亞太國家在 CIDP 市場中正在迅速發展。日本是一個醫療保健技術先進且注重研究的地區,大量的專利和臨床試驗證明了這一點。中國和印度因其人口眾多以及對包括 CIDP 在內的自體免疫疾病的認知不斷提高而成為重要市場。
FPNV定位矩陣
FPNV定位矩陣對於評估慢性發炎去髓鞘化多發性神經病變市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對發炎去髓鞘化多發性神經病變市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.慢性發炎去髓鞘化多發性神經病變市場的市場規模與預測是多少?
2.在慢性發炎去髓鞘化神經病變市場的預測期內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.慢性發炎去髓鞘化多發性神經病變市場的技術趨勢和法規結構是什麼?
4.發炎去髓鞘化神經病變市場主要供應商的市場佔有率為何?
5.進入慢性發炎去髓鞘化多發性神經病變市場的合適型態和策略性手段是什麼?
[187 Pages Report] The Chronic Inflammatory Demyelinating Polyneuropathy Market size was estimated at USD 2.35 billion in 2023 and expected to reach USD 2.49 billion in 2024, at a CAGR 5.81% to reach USD 3.49 billion by 2030.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neuromuscular or autoimmune disorder categorized by impaired sensory function in the legs and arms. The condition stems from the immune system mistakenly attacking the protective covering of the nerves, also known as the myelin sheath. This leads to slow nerve signal conduction, causing muscle weakness, reflex loss, and sensory problems. CIDP is paramount in neurology due to its chronic nature and significant impact on patient's quality of life. Rapid identification and appropriate therapeutic intervention are crucial in managing the symptoms and improving outcomes, highlighting the importance of ongoing research and development in treatments targeting this debilitating disorder. The rising concerns about neurological disorders and favorable government initiatives to support the treatment of these disorders propel the demand for CIDP treatment. However, the high cost associated with the CIDP is a significant challenge for the manufacturers and end users. Companies are constantly working towards research and development (R&D) and introducing novel drugs to remain agile within the landscape. Moreover, the Innovations in diagnostics and therapeutics for CIDP improve patient outcomes, thereby driving demand. Innovation and research include the development of more effective and less invasive treatment methods, novel diagnostic tools for early and accurate detection, and exploring the genetic basis of CIDP to uncover new therapeutic targets.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.35 billion |
Estimated Year [2024] | USD 2.49 billion |
Forecast Year [2030] | USD 3.49 billion |
CAGR (%) | 5.81% |
Treatment: Increasing usage of human intravenous immunoglobulin G in CIDP treatment to cater better patient outcomes
Chronic inflammatory demyelinating polyneuropathy (CIDP) management encompasses a holistic approach designed to dampen the improper immune reaction while enhancing the patient's quality of life. At the forefront of treatment protocols is administering intravenous immunoglobulin (IVIG), which supplies antibodies to adjust the immune system's functionality. Corticosteroids such as prednisone, which alleviate inflammation and modulate the immune system's vigor, are equally critical. Plasmapheresis represents an alternative strategy involving blood purification to eliminate deleterious antibodies for patients unresponsive to these treatments. Integral to the treatment regimen, physiotherapy aims to preserve and improve muscle strength, suppleness, and operational capacity, thereby playing an indispensable role in the comprehensive care approach for CIDP.
End-Use: Widening availability of CIDP treatment in hospitals and clinics to ensure broader accessibility to effective treatment regimens
Hospitals emerge as key facilities for initial diagnosis and treatment, providing comprehensive care, including intravenous immunoglobulin (IVIg) therapy, which demands specialized medical equipment and expertise. Specialty clinics offer a focused approach, catering to ongoing management and specialized treatments with professionals with in-depth knowledge of CIDP. Homecare settings are gaining prominence in maintaining the continuum of care, especially for long-term treatments, including subcutaneous immunoglobulin (SCIg) therapy, allowing patients comfort and convenience while minimizing hospital visits. Each of these settings offers distinct advantages and caters to the specific needs of the CIDP patient population, ensuring broader accessibility to effective treatment regimens.
Regional Insights
In the Americas, particularly the United States and Canada, there is a growing awareness and diagnosis rate of CIDP, driving demand for effective treatments. Patient-centric healthcare systems and high purchasing power produce strong customer purchasing behavior for innovative therapies. Significant R&D investments, coupled with favorable healthcare policies, support the growth of the CIDP market. Recent FDA approvals for CIDP treatments underscore the region's commitment to addressing this debilitating condition. On the other hand, European Union (EU) countries show a diverse landscape regarding CIDP awareness, diagnosis, and treatment access. Healthcare systems in the EU prioritize equitable access, with various countries adopting different models, including CIDP, to support rare disease treatments. Recent EU-wide initiatives focus on enhancing research, streamlining regulatory pathways, and fostering cross-border healthcare cooperation, aiming to improve patient outcomes across the continent. Asia Pacific countries such as China, Japan, and India are rapidly evolving in the CIDP market space, driven by increasing healthcare spending and improving diagnostic capabilities. Japan is in the region with advanced healthcare technologies and a strong focus on research, demonstrated by the high volume of patents and clinical trials. China and India are significant markets due to their large populations and growing awareness of autoimmune diseases, including CIDP.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Chronic Inflammatory Demyelinating Polyneuropathy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Chronic Inflammatory Demyelinating Polyneuropathy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Chronic Inflammatory Demyelinating Polyneuropathy Market, highlighting leading vendors and their innovative profiles. These include Avalon Pharma Pvt Ltd., Baxter International, Inc., Biotest AG, CSL Limited, F. Hoffmann-La Roche Ltd., Green Cross Corporation, Grifols, S.A., Johnson & Johnson Services, Inc., Kedrion Biopharma, Lee BioSolutions, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Viatris Inc., and Zai Lab Limited.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Chronic Inflammatory Demyelinating Polyneuropathy Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Chronic Inflammatory Demyelinating Polyneuropathy Market?
3. What are the technology trends and regulatory frameworks in the Chronic Inflammatory Demyelinating Polyneuropathy Market?
4. What is the market share of the leading vendors in the Chronic Inflammatory Demyelinating Polyneuropathy Market?
5. Which modes and strategic moves are suitable for entering the Chronic Inflammatory Demyelinating Polyneuropathy Market?